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Introduction
Gene therapy strategy of transducing cancer cells with herpes simplex virus thymidine kinase gene (HSVtk) to confer sensitivity to prodrug ganciclovir (GCV) has been well known and exploited in clinical trials. [1] [2] [3] The kinase encoded by HSVtk is about three orders of magnitude more efficient than cellular nucleoside kinase in catalyzing this guanosine analogue into its monophosphate form that can then be converted into GCV triphosphate by cellular nucleotide kinases. 4 GCV triphosphate is presumably toxic to the cells by inhibiting DNA polymerases or by being itself incorporated into DNA to cause chain termination. 5 Thus, cancer cells transduced with HSVtk become 'suicidal' upon exposure to GCV. An additional important feature of this strategy is the 'bystander' effect, namely the spread of the cytocidal effect of GCV to neighboring cells that do not receive the suicide gene. 6 Studies with colorectal carcinoma, glioma and melanoma cells 7 have concluded that the GCV killing of HSVtk-transduced tumor cells, as well as the 'bystander' effect is manifested by apoptosis, such as fragmentation of chromatin DNA revealed by the electrophoretic 'laddering pattern', 8 although another study using the same parameter on rat hepatoma cells reached the opposite conclusion. 9 In our previous study, kinetic analysis with additional indicators showed that apoptosis could indeed be induced by the HSVtk/GCV strategy but was slow in occurrence and preceded sequentially by p53 elevation and cell cycle S-phase retardation as well as G2 arrest, which might vary in different tumors. 7 Transduction with the bcl-2 gene was reported to confer resistance to the HSVtk/GCV induction of apoptosis and the bystander effect. 10 However, we did not detect alterations of Bcl-2 or Bax protein levels during induction of apoptosis in HSVtk-transduced murine B16F10 melanoma cells treated with GCV. In this study we have found that the apoptosis signal pathway of Fas (CD95/APO-1) receptor, Fas ligand (FasL) and associated regulators [11] [12] [13] [14] can be induced and thus responsible for most of the cell killing by the HSVtk/GCV strategy in four different murine tumors including B16F10 melanoma, NG4TL4 sarcoma, H6 hepatoma and 1MEA 7R.1 hepatoma.
Results

GCV-induced cytotoxicity in four murine tumor cells transduced with the HSVtk gene HSVtk and neo
R genes in bi-cistronic form were together introduced into cultured cells of C57BL/6 mouse melanoma B16F10, NIH Swiss mouse sarcoma NG4TL4, A/J mouse hepatoma H6, and Balb/c mouse hepatoma 1MEA 7R.1 through retroviral vectors or by DNA transfection. Isolated HSVtk-transduced cell clones of these four different murine tumors (designated B16F10/TK-C19, NG4TL4/TK-C3, H6/TK-C10 and 1MEA 7R.1/TK-C1, respectively), when exposed to culture medium containing 10 m GCV, showed growth inhibition and then cell death in 2-3 days. Dose response curves of the GCV cytotoxicity at 96 h revealed considerable variations ( Figure 1 ). The estimated IC 50 s, or concentrations of GCV causing 50% inhibition were 0.05 m in NG4TL4/TK-C3 sarcoma cells, 0.05 m in 1MEA 7R.1/TK-C1 hepatoma cells, 0.28 M in B16F10/TK-C19 melanoma cells and 0.52 M in H6/TK-C10 hepatoma cells. Non-transduced cells of these four tumors showed no growth inhibition or cell death even in 1 mm GCV, but could become equally sensitive to GCV in mixed culture with the respective transduced sibling tumor cells, revealing the 'bystander' effect (data not shown).
We previously observed that HSVtk-transduced B16F10 melanoma cells treated with 3 m GCV showed an early elevation of the p53 protein level, followed by cell cycle S-phase retardation in 18-24 h, G2-phase arrest in 24-48 h and finally apoptosis in 60 h or more. 7 When exposed to 1 to 50 m (ie 20-to 100-fold the respective IC 50 ) of GCV in the medium, NG4TL4/TK-C3 sarcoma, 1MEA 7R.1/TK-C1 hepatoma and H6/TK-C10 hepatoma showed similar response of p53 elevation, cell cycle arrest and finally signs of apoptosis, although with slight variations in the kinetics and extent of these responses ( Figure 1 ). Signs of apoptosis, which included electrophoretic laddering of nucleosomal DNA, an increase in in situ DNA-end labeling of nuclei, cells with sub-G1 DNA contents in cytofluorometric analysis, and specific binding of cell surface annexin V, appeared to be more marked with B16F10/TK-C19 cells and 1MEA 7R.1/TK-C1 cells than NG4TL4/TK-C3 sarcoma and H6/TK-C10 hepatoma cells (data not shown).
Induction of Fas and FasL before apoptosis
To investigate the underlying molecular mechanism of the induced apoptosis in these HSVtk/GCV-treated murine tumor cells, immunoblot analyses of the apoptosis-related cellular proteins were performed. Previously no alteration of Bax protein level was detected in B16F10/TK-C19 melanoma cells during GCV-induced apoptosis, while Bcl-2 content was below the detectable level by the immunoblotting method used, making it impossible to determine whether Bcl-2 played a role in the HSVtk/GCV-induced apoptosis. Figure 2 , the cellular levels of FasL and Fas proteins in HSVtk-transduced cells were increased in 30 h to 60 h after GCV treatment. The increases were more obvious in B16F10/TK-C19 melanoma and H6/TK-C10 hepatoma, which had relatively low basal levels of FasL and Fas, than in 1MEA 7R.1/TK-C1 hepatoma and NG4TL4/TK-C3 sarcoma with relatively high basal levels of Fas and FasL. Densitometric measurement of the relative quantities of Fas and FasL proteins revealed that both the increase of FasL and Fas proteins occurred later than the increase of cellular p53 protein level but before the appearance of apoptosis (Figures 2 and 3 ). In addition, two kinetic patterns of Fas and FasL responses were noted among the four murine tumors. In B16F10/TK-C19 and H6/TK-C10 tumor cells, a 10-to 30-fold increase of Fas at 24-60 h preceded a 10-fold increase of FasL at 36-60 h (Figure 3a and c), whereas in NG4TL4/TK-C3 and 1MEA 7R.1/TK-C1 tumor cells a two-to five-fold increase of FasL occurred earlier than the slightly or barely detectable increase of Fas (Figure 3b and d). In control experiments, non-transduced parental tumor cells treated with GCV showed the basal Fas and FasL levels without kinetic changes or signs of apoptosis. The basal levels of Fas and FasL proteins of all four tumors appeared to be slightly higher in the HSVtk-transduced than in the non-transduced sibling tumor cells.
Induction of FasL in vivo
Since the increased FasL protein appeared to occur at the initiation of the apoptosis process in the HSVtk/GCVtreated tumor cells in vitro, animal experiments were carried out to determine such occurrences in vivo. Subcutaneous tumors were produced by inoculating B16F10/TK-C19 melanoma cells and 1MEA 7R.1/TK-C1 hepatoma cells, respectively, into C57BL/6 and Balb/c mice. Seven days later, these tumor-bearing mice were injected intraperitoneally with 150 mg GCV per kilogram body weight twice daily for 5 consecutive days. In contrast to the in vitro observation of IC 50 , B16F10/TK-C19 tumors showed rapid regression and completely disappeared in 7-10 days following GCV treatment, while regression of 1MEA 7R.1/TK-C1 tumors occurred in 10-14 days. Immunohistochemical analysis of the tumors 423 immediately following GCV treatment showed that induction of FasL was rather marked in B16F10/TK-C19 melanoma and moderate in 1MEA 7R.1/TK-C1 hepatoma, consistent with the different rates of tumor regression ( Figure 4 ).
Downstream apoptosis regulators/effectors and cysteine protease activities
As B16F10/TK-C19 melanoma cells showed the most conspicuous induction of Fas and FasL by GCV treatment, they were examined for kinetic changes of three downstream regulators/effectors in the apoptosis signal pathway elicited by Fas and FasL interaction.
14 These included receptor-interacting protein (RIP) that contains a 'death domain' able to interact with the Fas 'death domain' for initiating the intracellular apoptotic signals; 15 caspase-3, the major apoptosis-associated cysteine protease that is activated after proteolytic cleavage by ICElike protease; 16, 17 and poly(ADP-ribose) polymerase or PARP, 18 a substrate of caspase-3 enzyme in regulating apoptosis in response to environmental stress, such as DNA damage. The results indicate that addition of 3 m GCV in the culture medium apparently caused all three downstream regulators/effectors to become activated in B16F10/TK-C19 cells ( Figure 5 ). Kinetically, the increased levels of RIP paralleled those of FasL, both with an apparent peak level at 48 h that was significantly behind the 36 h peak level of Fas protein. The 32 kDa proenzyme caspase-3 was slightly increased while the cleaved active 17 kDa caspase-3 protein rose slightly behind to reach a peak at 60 h. Beginning at 24 h, the protein level of PARP fragment (86 kDa) appeared to increase only slightly and gradually. In control experiment, Fas, FasL, RIP, caspase-3 and PARP proteins all remained at the respective basal levels in the non-transduced B16F10 melanoma cells throughout the GCV exposure ( Figure 5b , lower panel).
The above results with B16F10/TK-C19 melanoma cells suggested that the appearance of 17 kDa active caspase-3 protein followed the rise of FasL protein level rather than that of Fas protein level. It would be of interest to determine if this applied to other tumor cells, particularly GCV-treated 1MEA 7R.1/TK-C1 hepatoma cells in which the increase of FasL kinetically preceded that of Fas ( Figure 3 ). To quantify the kinetic changes of caspase-3 more precisely, the enzyme activity in cell extracts of GCV-treated B16F10/TK-C19 and 1MEA 7R.1/TK-C1 cells was measured by using a chromogenic tetrapeptide substrate, Asp-Glu-Val-Asp-pNA (Ac-DEVD-pNA), with or without the addition of a specific inhibitor, Ac-DEVD-CHO, or Tyr-Val-Ala-Asp-CHO (Ac-YVAD-CHO) that can specifically inhibits caspase-1 (ICE-like enzyme) but not caspase-3. 19 As shown in Table 1 , the peak of caspase-3 activity in GCV-treated B16F10/TK-C19 melanoma cells occurred at 48-60 h, confirming the immunoblot results, while the peak activity in GCV-treated 1MEA 7R.1/TK-C1 hepatoma cells was detected at 24-48 h. The results clearly indicate that indeed the activation of caspase-3, as well as apoptosis, kinetically followed the induction of FasL protein in the HSVtk-transduced GCV-treated tumor cells.
Abrogation of apoptosis by blocking Fas/FasL interaction and the effector pathway
Three experiments were performed to determine if blocking the Fas/FasL signal pathway could abrogate cell death in HSVtk-transduced tumor cells treated with GCV. First, for the purpose of inhibiting FasL protein synthesis, FasL-specific antisense oligonucleotides were included in the culture medium of HSVtk-transduced 1MEA 7R.1/TK-C1 hepatoma cells 2 h before the GCV treatment. As shown in Figure 6 , this measure could inhibit the increase of FasL protein level, the activation of caspase-3 activation, and the appearance of DNA laddering, with cell viability raised to 80% from 30%. The effects of the FasL-specific antisense oligonucleotides were specific and dose dependent (Figure 6a ), since the same high concentrations of the FasL sense oligonucleotides showed no similar effects on GCV-treated HSVtk-transduced cells. Neither oligonucleotides affected the viability of HSVtktransduced tumor cells not treated with GCV. Second, experiments were performed to block HSVtk/GCVinduced FasL from binding to its receptor and thus prevent the initiation of apoptosis cascade. Initially, an anti-human FasL monoclonal antibody that presumably could recognize human FasL was added to the culture medium of transduced tumor cells before and during GCV treatment. However, no abrogating effect was obtained. We therefore tested a recombinant Fas/Fc chimeric protein that contains the extracellular domain of human Fas and can thus compete with the membrane Fas receptor for binding to FasL. Positive results were obtained, showing dose-dependent abrogation of apoptosis by the rhFas/Fc protein and raising cell viability to a plateau of around 75%, in contrast to 30% viability of GCV-treated 1MEA 7R.1/TK-C1 cells not exposed to this chimeric protein (Figure 7) . Third, we determined if inhibition of the activated caspase-3 further down the Fas/FasL pathway could affect apoptosis by the HSVtk/GCV strategy. Cell-permeable specific inhibitors of caspase-3 (tetrapeptide fluoro-or chloro-methylketone, Z-DEVD-FMK and Ac-DEVD-CMK) and specific inhibitor of FLICE/caspase-8 (IETD-FMK), added to the cell culture before and during GCV treatment, raised the cell viability to a plateau of around 75% from the control level of 30%, whereas another tetrapeptide (Ac-YVAD-CHO) was not significantly effective ( Figure 8 ).
Discussion
In the present study, we have obtained experimental evidence to indicate that the HSVtk/GCV strategy of gene therapy may induce apoptosis through the activation of Fas/FasL pathway in four different mouse tumors, ie melanoma B16F10, sarcoma NG4TL4, and two hepatoma H6 and 1MEA 7R.1. The observation of apoptosis is consistent with the conclusion of previous studies on various tumors, such as glioma and colorectal carcinoma. 6, 8 However, not only were the GCV IC 50 s different, but also signs of apoptosis varied considerably among the four tumors, with B16F10 melanoma being the most marked and H6 hepatoma the least apparent. It generally took 48 to 72 h for the apoptotic cell death to appear following at least 18 h exposure of these tumor cells to the respective cytotoxic doses of GCV. The inhibitory and damaging effects of GCV nucleotides 4,5 apparently proceeded through elevation of p53 protein level, cell cycle S-phase retardation and G2-phase arrest before the activation of the apoptotic mechanism. 7 Also, variations were observed in the basal as well as the stimulated levels of Fas and FasL proteins, which might be due to genetic polymorphism in different mouse strains. 20 Furthermore, IC 50 of GCV determined in vitro was lower for 1MEA7R.1/TK-C1 hepatoma cells than for B16F10/TK-C19 melanoma cells, but GCV-induced tumor regression was more marked in the latter than the former. Thus, the variations in GCV cytotoxic dose and kinetics of apoptosis responses would be important for considering the application of HSVtk/GCV strategy to individual tumors.
Recent studies have established the apoptosis pathway initiated by the interaction of Fas/TNF receptor family and their respective ligands 14 and also recognized the important regulatory roles played by the Bcl-2 and related family of proteins. [21] [22] [23] [24] We have observed that the elevation of cellular FasL and Fas was kinetically correlated with apoptosis induced in all four murine tumors subjected to the HSVtk/GCV strategy in vitro and in vivo. Furthermore, this apoptosis could be abrogated by applying inhibitors to block the pathway at three points, namely by pretreatment with a specific antisense oligonucleotide to inhibit FasL synthesis, by treatment with a recombinant human Fas/Fc chimeric protein to inhibit FasL interaction competitively with its receptor, and by treatment with a specific peptide inhibitor to prevent the activated caspase-3 from acting on its cellular targets. These treatments consistently showed decrease of cell death from 70-80% down to about 20-25%, or increase of cell viability from 20-30% to 75-80% (Figures 6-8) , suggesting that at least half of the cell death in the murine tumor cells subjected to HSVtk/GCV gene therapy strategy was mediated by activation of Fas/FasL-initiated apoptosis pathway.
The fact that elevation of p53 protein level precedes that of the Fas induction is consistent with the previous finding that over-expression of p53 may activate the transcription of fas gene. 25 It is not known if p53 would act similarly on fasl gene expression, although no transcriptional cis element for p53 recognition has been found in fasl. Recently, it was reported that doxorubicin-induced apoptosis in human hepatoma cells was mediated by the Fas (CD95/APO-1) receptor/Fas ligand system and involved activation of wild-type p53. 26 This is similar to the present finding with the murine tumor cells. On the other hand, it was reported that apoptosis induced by doxorubicin treatment in human acute T-lymphatic leukemia cells could not be blocked by specific inhibitory cowpox viral protein CrmA nor by anti-FasL monoclonal antibody, suggesting a Fas/FasL-independent mechanism of doxorubicin-induced cell killing. 27 In addition, kinetics of FasL stimulation and apoptosis induced by the HSVtk/GCV strategy are different from those induced by doxorubicin, which occur in a few hours rather than a few days of the drug treatment. 28 Whether the apparent similarity and difference between doxorubicin treatment and HSVtk/GCV strategy are due to the cell system (solid tumors versus leukemia), the underlying apoptosis mechanism or the reagents used for the study remains to be determined. In this regard, it has been shown that bcl-2 can inhibit Fas-induced cell death. 29, 30 Indeed, exogenous bcl-2 gene transduction was reported to prevent the induction of apoptosis by GCV in HSVtk-transduced cells. 10 Thus, although we did not detect Bcl-2 or Bax protein level change in HSVtk-transduced B16F10 melanoma cells following GCV treatment, 7 it remains to be determined whether or not the cellular content of Bcl-2 and related proteins may affect the extent and signs of GCVinduced apoptosis in various HSVtk-transduced tumors.
With the findings of 'death domain'-containing proteins such as RIP, 15 elucidation of functional roles of interleukin-1␤-converting enzyme (ICE/caspase-1) and related cysteine protease, particularly caspase-3, [16] [17] [18] [19] and demonstration of poly(ADP-ribose) polymerase (PARP) 18 as a substrate for caspase-3, schemata of major pathways of apoptosis have been postulated. 14 The results of our kinetic analysis ( Figure 5 and Table 1 ) would support that RIP and caspase-3 play key roles in the Fas/FasL apoptosis pathway of these murine tumors, although the possible participation of PARP remains to be clarified. Also, it was shown that caspase-1 served a catalytic role to activate caspase-3; 16 however, using specific Ac-YVAD-pNA tetrapeptide substrate, we did not detect any significant increase in caspase-1 activity before the increase of activated caspase-3 (data not shown). Fluoroor chloro-methylketone derivatives of specific tetrapeptide substrates for caspase-8 as well as caspase-3 could abrogate the apoptosis (Figure 8 ), suggesting the involvement of caspase-8 and caspase-3 downstream of the HSVtk/GCV-induced, FasL/Fas-initiated apoptosis pathway.
One major attractive feature of the HSVtk/GCV gene therapy strategy is the 'bystander' effect. Cell-cell communication through membrane gap junctions involving connexin 43, but not connexin 32, was shown to be a major factor for the bystander effect. [31] [32] [33] However, the bystander effect could be complex and might involve more than one factor. The present finding of FasL induction would provide another possible mechanism. Although we have not determined if Fas and FasL induction would occur in the same cell and result in intracellular FasL/Fas interaction, our results with the use of recombinant Fas/Fc chimeric protein (Figure 7 ) would suggest that apoptosis is most likely due to interaction of FasL on one cell and Fas receptor on another. Thus, the FasL expressed on the surface of HSVtk-transduced tumor cells might interact with its receptor, Fas, on the neighboring non-transduced tumor cells and thus elicit the apoptosis signal pathway in the latter cells. As FasL protein can also be released from the cell surface by metalloproteinase and then enter circulation, whether or not this could account for the 'distant bystander effect' 34, 35 would be of interest. Finally, given that organs such as central nervous system, eye, testis 36 and certain tumors 28, [37] [38] [39] can maintain immune privilege and tolerance by expression of FasL, the possibility that FasL expression stimulated by the HSVtk/GCV treatment may result in the elimination and/or functional alteration of Fas-containing tumor-infiltrating lymphocytes in vivo would require further investigation. 
Materials and methods
Drugs and reagents GCV (Cymevene) was obtained from Syntex (Palo Alto, CA, USA). The antibodies for protein blotting assay were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) (anti-Fas and Cdc2 antibodies), Transduction Laboratories (Lexington, KY, USA) (anti-FasL and RIP antibodies), Oncogene Sciences (Cambridge, MA, USA) (anti-p53 antibody) and Pharmingen Biotechnology (San Diego, CA, USA) (anti-caspase-3 and PARP antibodies). The FasL-specific antisense 1 (5′-CTGCATG GCACCCAGCCCCAG-3′) or antisense 2 (5′-CAT GGGCTGCTGCATGGCACC-3′) and sense 1 (5′-GAC GTACCGTGGGTCGGGGTC-3′) or sense 2 (5′-GGTG CCATGCAGCAGCCCATG-3′) phosphorothioates oligonucleotides were synthesized and purified by high performance liquid chromatography by Genset (Paris, France). Recombinant human Fas/Fc chimeric protein was from R&D Systems (Minneapolis, MN, USA). Both chromogenic substrates (Ac-DEVD-pNA for caspase-3 and Ac-YVAD-pNA for caspase-1) and inhibitors (Ac-DEVD-CHO for caspase-3 and Ac-YVAD-CHO for caspase-1) were from BioMol Research Laboratories (Plymouth Meeting, PA, USA). Cell-permeable specific inhibitors of caspase-1 (Ac-YVAD-CHO), caspase-3 (Z-DEVD-FMK and Ac-DEVD-CMK) and caspase-8 (IETD-FMK) were from CalBiochem-NovaBiochem (San Diego, CA, USA).
Mouse and tumor cell lines
Six-to 8-week-old female syngeneic C57BL/6 or Balb/c mice were obtained from central animal facility of the Taiwan University Medical Center. All mice were maintained and handled according to the US NIH guidelines. B16F10 melanoma cells was given kindly by Dr IJ Fidler (MD Anderson Cancer Center, University of Texas, Houston, TX, USA); NG4TL4 sarcoma cells were from our own laboratory; 40 H6 hepatoma cells from Jackson Laboratory and 1MEA 7R.1 hepatoma cells from American Type Culture Collection (ATCC, Bethesda, MD, USA). All these tumor cells and their transfected descendants were grown in 5% CO 2 incubator at 37°C in minimal essential medium (MEM) (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone, Logan, UT, USA), 2 mm of l-glutamine, 100 U/ml of penicillin and 100 g/ml of streptomycin sulfate (all from Life Technologies, Gaithersburg, MD, USA). Cell lines used in this study were free of mycoplasma infection.
Transduction of murine tumor cell lines B16F10 melanoma cells and NG4TL4 sarcoma cells were infected with packaged virions of a recombinant retroviral vector constructed to contain HSV-1-tk gene 41 Technologies) . Subsequently, individual B16F10/TK, H6/TK and 1MEA 7R.1/TK cell clones were isolated by selection in growth medium containing 375 g/ml geneticin (G418; Sigma) for 2 weeks, except that NG4TL4 transduced cell clones were isolated by limit dilution and PCR detection of tk gene sequences. Presence of tk gene in the transduced cell clones was verified by PCR detection and on the basis of their sensitivity to the cytocidal effect of GCV.
Measurement of ganciclovir-induced cytotoxicity
The cytocidal effect of GCV was determined by colorimetric quantification of viable cells. 42 The parental and HSVtk-transduced B16F10/TK-C19, NG4TL4/TK-C3, H6/TK-C10 or 1MEA 7R.1/TK-C1 tumor cells were plated, respectively, on 96-well plates at a density of 2 × 10 4 . Cells were treated on day 0 with GCV at a concentration of 0, 0.01, 0.1, 0.5, 1.0, 10 and 100 m. Medium was changed on day 2 with the respective fresh GCVcontaining medium. Ninety-two hours later, 50 l of 0.5% MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma) in phosphate-buffered saline (PBS) was added, incubated for 4 h, removed and replaced with 100 l of dimethyl sulfoxide (DMSO; Merck) to extract formazan. The color reaction was measured using an ELISA reader (Bio-Rad) at 570 nm. The cell viability was also assessed by trypan blue exclusion staining.
Western blot analysis
After trypsinization, cells were washed with ice-cold PBS once and then solubilized in lysis buffer consisting of 50 mm Tris-HCl (pH 7.5), 4 mm EDTA, 2 mm EGTA, 10 mm DTT and 1 mm PMSF. Lysates were sonicated on ice and centrifuged at 100 000 g for 1 h at 4°C. The pellet and supernatant were stored at −80°C. Protein concentrations were determined by protein assay (Bio-Rad or Lowry method). Equal amounts of membrane or cytosolic protein (40 g) were separated respectively on 10% SDS/polyacrylamide gels and transferred to polyvinylidene difluoride membrane. The membrane blots were incubated with individually specific antibody reagents, which included anti-Fas (0.5 g/ml), anti-Cdc2 (0.5 g/ml), anti-FasL (1:1000), anti-RIP (1:1000), anti-caspase-3 (2 g/ml) and anti-PARP (4 g/ml) antibodies. Specific antibody-binding protein bands were revealed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG at 1:3000 dilution (Amersham). Protein bands of FasL, Fas, RIP, caspase-3, PARP and Cdc2 were detected by enhanced chemiluminescence (ECL) (Amersham). As the Cdc2 protein content in these tumors was not affected by the treatment, as observed previously, 7 membrane hybridized with anti-Cdc2 antibody served as an internal control. The results were further quantified by an AlphaImager 2000 densitometer (Alpha Innotech, Avery Dennison, CA, USA). For optimal image acquisition and maintenance of densitometric measurements within linear range, the 'saturation palette' was used as a modified gray scale palette in which black (gray level 0) is replaced with green, and white (gray level 255) is replaced with red. The spot density was measured and expressed by integrated density value (IDV), the sum of all the pixel values after background correction. The relative quantity was obtained by dividing the sample IDV (in various times of GCV-exposed samples) by control IDV.
Cell death assay Flow cytofluorometry was employed for the quantification of cells undergoing apoptosis. 43 Tumor cells were plated at a density of 1 × 10 6 cells per 10-cm dish. Twenty-four hours later, the cells were treated with or without 1, 3 or 50 m GCV in growth medium for 24, 48, 60 and 72 h. For measuring the cellular DNA content, 5 × 10 5 of cells were washed once with PBS and fixed in 80% ethanol at −20°C for at least 1 h. After centrifugation at 130 g for 5 min at 4°C, cell pellet was suspended in 0.5 ml of 0.1% Triton X-100 (Merck), incubated at room temperature for 30 min, washed with 1 ml of PBS and then mixed with 1 ml of 50 g/ml propidium iodide (PI; Sigma) plus 0.5% (w/v) of RNase A (Sigma) in the dark. After 10 to 30 min, the DNA content of individual cells was quantified by flow cytofluorometry (FACStar plus; Becton Dickinson).
DNA ladder assay
Cellular DNA fragments were isolated by the method described by Hermann et al 44 with minor modifications. After GCV and sense or antisense phosphorothioate oligonucleotides of FasL treatment, adherent and nonadherent cells were pooled and lyzed in 50 mm Tris-HCl (pH 7.5), 20 mm EDTA and 1% NP-40. After centrifugation for 1 min at 800 g, the supernatant was collected and the extraction of pellets repeated twice. Pooled supernatants were brought to 1% SDS, digested with DNase-free RNase A (final concentration 0.2 g/l) at 50°C for 1 h and then with proteinase K (final concentration 2.5 g/l) at 37°C overnight. After the digestion, DNA was isolated by phenol/chloroform extraction and ethanol precipitation and finally dissolved in 10 mm TrisHCl/1 mm EDTA solution (pH 7.6). The DNA preparations were separated in 1% agarose gel by electrophoresis and stained with ethidium bromide.
Immunohistochemical staining of tissue sections
To evaluate the induction of FasL on the GCV-exposed HSVtk-expressing tumor cells in vivo, 10 6 of parental HSVtk-negative B16F10 or 1MEA 7R.1 and HSVtk-positive B16F10/TK-C19 or 1MEA 7R.1/TK-C1 cells were inoculated subcutaneously into the left flank of female syngeneic C57BL/6 or Balb/c mice, respectively. Seven days later, mice were treated twice daily by intraperitoneal injection of 150 mg GCV per kg body weight for 5 consecutive days. Following the GCV treatment, the tumor mass was excised and fixed in 4% paraformaldehyde in sodium phosphate buffer (pH 7.4) for at least 4 h at 4°C and then processed for paraffin embedding. The specimen was cut into 4-to 6-m sections and mounted on glass slides. After deparaffinization, rehydration and permeabilization, endogenous peroxidase activity was quenched with 3% H 2 O 2 for 5 min. The cells were blocked with 8% bovine serum albumin (BSA)/PBS for 30 min at room temperature and incubated overnight at 4°C with 10 g/ml anti-FasL monoclonal antibody (Transduction Laboratories) in 1% BSA/PBS. After washing twice, the cells were incubated with a 1:100 dilution of goat anti-mouse IgG HRP-conjugated secondary antibody (Amersham) for 1 h at room temperature. Follow-ing incubation with HRP-specific substrate DAB solution (Sigma), the cells were counterstained with methyl green and mounted with permount (Sigma).
